Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ARIAD Announces Appointments of Key Members of Leadership Team

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Ready for anticipated regulatory approval and launch of Iclusig® in Europe this year.

ARIAD Pharmaceuticals, Inc. announced the appointment of Jonathan E. Dickinson to the position of General Manager, ARIAD Pharmaceuticals (Europe), Sàrl. Mr. Dickinson is a seasoned commercial executive bringing more than 20 years of pharmaceutical-industry experience to ARIAD, with special emphasis on global and pan-European leadership of several important cancer medicines. Mr. Dickinson is responsible for leading ARIAD’s European commercialization initiatives -- focused first on the anticipated European approval and launch of Iclusig® (ponatinib) in the third quarter of 2013 and subsequently on ARIAD’s other cancer medicines in development.

Mr. Dickinson joined ARIAD from Bristol-Myers Squibb, where he served for the past three years as the European brand lead for ipilimumab, responsible for the product’s European launch and commercialization in 29 countries. Previously, during his 13-year tenure at Hoffmann-La Roche, Mr. Dickinson held several key leadership positions, including lifecycle leader for capecitabine, where he managed global marketing, clinical development, regulatory affairs and manufacturing activities for the brand. At Roche, he had assignments both in the U.S. and Switzerland that included leadership roles of Roche’s three leading oncology medicines -- trastuzumab, rituximab, and capecitabine. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.

Mr. Dickinson received his B.Sc. degree in Genetics and his M.B.A. degree from the University of Nottingham. He is based at ARIAD’s European headquarters in Lausanne, Switzerland and reports to Marty J. Duvall, senior vice president, commercial operations of ARIAD.

“Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “His knowledge of the evolving European market and his success in commercializing important cancer medicines throughout Europe and globally will serve us well as we prepare for anticipated approval and commercialization of Iclusig in the EU this year.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ARIAD Presents Data for Investigational Inhibitor
New preclinical data showing AP26113 inhibits clinically relevant mutants of ALK and ROS1.
Thursday, April 11, 2013
ARIAD’s AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
Paper Features Design and Preclinical Characterization of AP24534; Data demonstrate inhibition of all known variants of the CML target protein.
Tuesday, November 03, 2009
ARIAD Announces Preliminary Results from Ongoing Clinical Trial of its Investigational Bcr-Abl Inhibitor
The study provides initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated CML patients.
Tuesday, July 28, 2009
ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Advanced Endometrial Cancer
Deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies.
Thursday, August 07, 2008
ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Breast Cancer Patients
ARIAD will receive a $15 million milestone payment from Merck for treating the first patient in the breast cancer clinical trial.
Tuesday, August 05, 2008
New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
ARIAD publishes the high-resolution structure of the protein responsible for a major clinically relevant genetic variant of drug-resistant chronic myeloid leukemia.
Wednesday, October 10, 2007
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!